血清淀粉样蛋白A与肿瘤诊断、分期和预后相关性研究进展  

Advances on the Correlation between Serum Amyloid A and Cancer Diagnosis,Stage and Prognosis

作　　者：刘振亚 赵慧敏 王临艳[1] LIU Zhen-ya;ZHAO Hui-min;WANG Lin-yan(Maternal and Child Health Hospital of Gansu Province,Lanzhou 730050,China)

机构地区：[1]甘肃省妇幼保健院,兰州730050

出　　处：《现代检验医学杂志》2023年第3期207-212,共6页Journal of Modern Laboratory Medicine

基　　金：甘肃省科学技术厅自然科学基金项目(20JR10RA424)。

摘　　要：目前用于肿瘤诊断和肿瘤分期的方法多具有侵袭性,且部分肿瘤标志物敏感性较低,已不能满足临床需求。已有大量的研究表明:血清淀粉样蛋白A(serum amyloid A,SAA)与多种肿瘤的发生、发展密切相关,有较高的敏感度和特异度,无侵袭性、操作简单和成本低等优点。SAA联合其他肿瘤标志物及肿瘤检测方法在肿瘤诊断、病理分期和预后判定中发挥临床价值。该文就近年来SAA在多种肿瘤中的研究进展进行综述,为肿瘤患者个体化精准治疗、提升治疗效果、提高生存质量、提供理论支持。At present,most of the methods used for tumor diagnosis and tumor staging are invasive,and some tumor markers have low sensitivity and have been unable to meet the clinical needs.A large number of studies have shown that serum amyloid A(SAA)is closely related to the occurrence and development of a variety of tumors,and has a high sensitivity and specificity,and whether invasive,simple operation and low cost,combined with other tumor markers and tumor detection methods play a clinical value in tumor diagnosis,pathological staging and prognosis.This article reviews the research of SAA in a variety of tumors in recent years,providing theoretical support for individualized precise treatment of cancer patients,improving the therapeutic effect,and improving the quality of life.

关 键 词：血清淀粉样蛋白A(SAA) 肿瘤 生物标志物 

分 类 号：R730.43[医药卫生—肿瘤]